⚡ Metabolic 🔴 Essential

Fasting Blood Glucose

Your blood sugar level after not eating , the most basic snapshot of how your body manages sugar.

What is Fasting Blood Glucose?

Fasting glucose is a measure of the amount of glucose (sugar) in your bloodstream after an overnight fast of at least 8 hours. Glucose is the body's primary fuel source , it comes from carbohydrates and is managed by insulin, which signals cells to absorb it from the blood. Fasting glucose reflects how well the body maintains blood sugar stability in the absence of food intake and is one of the foundational markers of metabolic health.

Fasting glucose pairs with fasting insulin to provide a complete picture of metabolic health. While fasting glucose alone can appear normal even in early insulin resistance , because the pancreas compensates by producing more insulin , combining both allows calculation of HOMA-IR, the most widely used research measure of insulin resistance. Pre-diabetic glucose levels in the context of peptide research warrant metabolic-first evaluation before GH approaches are considered.

What do the numbers mean?

Optimal (functional target)
70–90 mg/dL
Functional medicine target after an 8–12 hour fast. This range reflects excellent insulin sensitivity and stable blood sugar regulation in the absence of food.
Standard Normal
70–99 mg/dL
Standard lab reference range for fasting blood sugar. Values in the 90–99 mg/dL range while technically normal may indicate developing insulin resistance when combined with elevated fasting insulin.
Out of Range , Note
100–125 mg/dL (pre-diabetes)
≥ 126 mg/dL (diabetes threshold)
100–125 mg/dL indicates pre-diabetes. Above 126 mg/dL on two separate occasions indicates diabetes. Below 70 mg/dL indicates hypoglycemia. Both extremes require clinical evaluation.

Lab reference ranges vary by laboratory, age, sex, and testing method. Always interpret your results with your healthcare provider , do not self-diagnose based on these ranges.

Why this marker matters before peptide research.

In GH secretagogue research, fasting glucose is monitored because GH elevation transiently reduces insulin sensitivity , which can push borderline glucose levels into pre-diabetic ranges during active protocols. A research protocol initiated at fasting glucose of 95 mg/dL with high fasting insulin already present represents a meaningfully different metabolic risk profile than one initiated at 78 mg/dL with optimal insulin. Knowing both before starting any GH protocol is essential context.

In GLP-1 agonist research, fasting glucose is a primary efficacy marker. The SUSTAIN, STEP, and SURPASS trial series all documented meaningful reductions in fasting glucose alongside weight loss and HbA1c improvement with semaglutide and tirzepatide. Establishing a pre-protocol baseline enables objective measurement of glycemic response over a research protocol timeline.

The combination of fasting glucose and fasting insulin (HOMA-IR) is the most sensitive research tool for identifying insulin resistance before it becomes detectable on standard metabolic panels. The formula is: HOMA-IR = (fasting insulin in µIU/mL × fasting glucose in mg/dL) ÷ 405. A result above 2.0 suggests insulin resistance; above 2.9 indicates moderate to significant resistance. Testing both simultaneously in a single fasted blood draw provides substantially more information than either marker alone.

How to get this test.

Where to order

Standard blood draw at any major lab , LabCorp, Quest Diagnostics, or through your physician. Included in most standard metabolic panels (BMP, CMP). Order alongside fasting insulin for HOMA-IR calculation in a single fasted draw.

How to prepare

Minimum 8–12 hours fasting required , no food or caloric beverages. Water is fine. Draw in the morning before any food intake. Avoid intense exercise the morning of the draw as it transiently lowers blood glucose and may not reflect a stable baseline.

What to ask for

"Fasting Glucose" or "Fasting Blood Sugar" , included in Basic Metabolic Panel (BMP) and Comprehensive Metabolic Panel (CMP). Can also be ordered as a standalone test. Pair with "Fasting Insulin" to calculate HOMA-IR in the same blood draw.

Peptides commonly researched in connection with this marker.

Semaglutide Fasting glucose is a primary efficacy endpoint in semaglutide research , trials consistently document meaningful reductions. Baseline fasting glucose establishes the starting point for monitoring glycemic response.
Tirzepatide Tirzepatide's dual GIP/GLP-1 mechanism produces robust fasting glucose reductions , monitoring this marker alongside HbA1c and fasting insulin gives the most complete metabolic response picture.
Retatrutide Triple agonist research protocols list fasting glucose as a primary safety and efficacy marker , elevated pre-protocol glucose warrants metabolic-first evaluation.
Ipamorelin GH elevation from Ipamorelin transiently reduces insulin sensitivity , fasting glucose establishes the metabolic safety baseline before and during a GH secretagogue protocol.
Tesamorelin Clinical trials of Tesamorelin included fasting glucose monitoring as a safety measure , GH-mediated glucose effects make pre-protocol glycemic status essential context.
MOTS-c MOTS-c research targets insulin sensitization via mitochondrial signaling , fasting glucose is the primary metabolic efficacy marker in MOTS-c research contexts.

Goals where this biomarker is most relevant.

Ready to build your baseline?

Use Pepvela's Lab Guide to understand which markers to test first, then use the Peptide Finder to match your biology to research-relevant compounds.

For educational and research purposes only. Not medical advice. Always consult a licensed healthcare provider before making any health decisions.